CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma

Colin W. Steele, Saadia A. Karim, Joshua D.G. Leach, +23

Cancer Cell

Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent

Kevin M. Foote, J. Willem M. Nissink, Thomas M. McGuire, +11

Journal of Medicinal Chemistry

Kinase Ataxia TelangiectasiaCell DeathMolecular BiologyPharmacotherapyCompound 2 +17

Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells

Rebecca L. Lloyd, Paul W.G. Wijnhoven, Antonio Ramos‐Montoya, +10

Oncogene

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and <i>ESR1</i> -Mutant Breast Tumors in Preclinical Models

Hazel M. Weir, Robert H. Bradbury, Mandy Lawson, +26

Cancer Research

Optimization of a Novel Binding Motif to (<i>E</i>)-3-(3,5-Difluoro-4-((1<i>R</i>,3<i>R</i>)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1<i>H</i>-pyrido[3,4-<i>b</i>]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist

Chris De Savi, Robert H. Bradbury, Alfred A. Rabow, +23

Journal of Medicinal Chemistry

Pharmaceutical SciencePharmacotherapyPositive Breast CancerPharmaceutical ChemistryMolecular Pharmacology +16

Identifying strategies to target the metabolic flexibility of tumours

Andrés Méndez‐Lucas, Wei Lin, Paul C. Driscoll, +13

Nature Metabolism

Metabolic RemodelingMetabolic Pathway AnalysisMetabolic FlexibilityMedicineCell Biology +3

Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family

Sandra R. Brave, Kirsty Ratcliffe, Zena Wilson, +17

Molecular Cancer Therapeutics

Vegfr-1 Tyrosine KinaseAngiogenesisMedicineReceptor Tyrosine KinaseCancer Growth +10

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

Violeta Serra, Anderson T. Wang, Marta Castroviejo‐Bermejo, +37

Clinical Cancer Research

Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress

Lucy A. Young, Lenka Oplustil O'Connor, Christelle de Renty, +11

Cancer Research

PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors

Anna D. Staniszewska, Joshua Armenia, Matthew King, +14

OncoImmunology